David Hoang
Stock Analyst at Deutsche Bank
(n/a)
# 3,337
Out of 4,829 analysts
38
Total ratings
n/a
Success rate
-54.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Buy | $40 → $52 | $31.27 | +66.29% | 2 | Mar 27, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Hold | $124 → $99 | $36.37 | +172.20% | 6 | Mar 19, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $35.85 | +86.89% | 3 | Feb 11, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $111 | $38.42 | +188.91% | 1 | Feb 11, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $55 | $35.65 | +54.28% | 2 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $14.80 | +109.46% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $20.56 | +216.15% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $110.16 | +59.77% | 4 | Feb 11, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | $12 | $9.59 | +25.13% | 1 | Feb 11, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $30 → $23 | $17.52 | +31.28% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $120.43 | +31.20% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.05 | +566.67% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $8 | $6.75 | +18.52% | 1 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.90 | +451.72% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.35 | +377.61% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $270.19 | -18.58% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $13.97 | +472.66% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $1.10 | +172.73% | 1 | Dec 7, 2022 |
Alkermes
Mar 27, 2025
Maintains: Buy
Price Target: $40 → $52
Current: $31.27
Upside: +66.29%
Sarepta Therapeutics
Mar 19, 2025
Maintains: Hold
Price Target: $124 → $99
Current: $36.37
Upside: +172.20%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $35.85
Upside: +86.89%
Praxis Precision Medicines
Feb 11, 2025
Initiates: Buy
Price Target: $111
Current: $38.42
Upside: +188.91%
Harmony Biosciences Holdings
Feb 11, 2025
Initiates: Buy
Price Target: $55
Current: $35.65
Upside: +54.28%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $14.80
Upside: +109.46%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $20.56
Upside: +216.15%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $110.16
Upside: +59.77%
Avadel Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $9.59
Upside: +25.13%
ACADIA Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $30 → $23
Current: $17.52
Upside: +31.28%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $120.43
Upside: +31.20%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.05
Upside: +566.67%
May 29, 2024
Initiates: Sell
Price Target: $8
Current: $6.75
Upside: +18.52%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $2.90
Upside: +451.72%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $3.35
Upside: +377.61%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $270.19
Upside: -18.58%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $13.97
Upside: +472.66%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $1.10
Upside: +172.73%